Search for "weight loss tablets UK" and you'll find everything from established pharmacy medicines to unregulated products making bold claims with no oversight at all. It's a crowded space, and not everything sold as a weight-loss pill is actually a medicine that has been through the UK's licensing process.
This guide sets out what is genuinely licensed for weight loss in tablet form in the UK, how those tablets compare with the weekly injections most people associate with this treatment area, what to be wary of online, and how a clinician decides what, if anything, is appropriate for you.
Licensed oral options: orlistat, and the newer GLP-1 tablets
The longest-standing licensed weight-loss tablet in the UK is orlistat, which works by blocking around a quarter of the fat absorbed from a meal in the gut rather than acting on appetite. It comes in two UK products: Alli (60 mg), a pharmacy medicine a pharmacist can supply after a short consultation, and Xenical (120 mg), the higher-strength prescription-only version.
More recently, the GLP-1 medicines familiar as weekly injections have started arriving in tablet form. Wegovy Oral is an oral semaglutide tablet licensed specifically for weight management, dosed at higher strengths to match that indication. Rybelsus is a separate oral semaglutide product, licensed for type 2 diabetes rather than weight loss, though some clinicians have used it off-label for weight in selected patients. Foundayo (orforglipron), covered in more detail in our guide to Foundayo's approval, is a newer once-daily GLP-1 tablet with a different active ingredient again, and, unlike Rybelsus, no fasting or water-restriction rules around dosing.
Beyond Mounjaro (tirzepatide), which remains injection-only in UK practice at the time of writing, this is the full list of what is actually licensed. Anything else marketed as a weight-loss tablet, whether it borrows the name of a known medicine or invents a new one, sits outside this list.
How tablets compare with weight-loss injections
The GLP-1 tablets share the same underlying mechanism as the injections: they act on appetite signalling and slow gastric emptying via the GLP-1 pathway, which is why trial data for products such as Wegovy Oral and Foundayo shows weight loss in a broadly similar range to their injectable equivalents. Orlistat works completely differently, reducing fat absorption rather than appetite, and its average effect on weight tends to be more modest as a result.
Practically, tablets remove the need to store or dispose of sharps and can suit people who are needle-averse, but some come with their own routine: Rybelsus needs to be taken on an empty stomach with limited water, while Wegovy Oral and Foundayo have simpler dosing rules. There's no cold-chain storage to think about with a tablet either, which can matter if you travel a lot, and a missed dose is simply picked up the next day rather than involving the timing arithmetic of a weekly injection. Set against that, a once-weekly injection means one dosing decision a week rather than a daily one, which some people find easier to build into a routine than remembering a tablet every day. Neither format is universally "better"; the right choice depends on tolerability, lifestyle and what a clinician judges suitable for you specifically.
What weight-loss pills sold online actually are
A large share of what shows up when searching for weight-loss pills has nothing to do with the medicines above. Some products are food supplements with no meaningful evidence behind them; others are marketed using the name or imagery of a known medicine without being that medicine at all. Buying from a website outside the UK's regulated pharmacy system means there is no verification of what the product actually contains, at what dose, or whether it is safe to take alongside your other medicines.
The UK's regulator, the MHRA, has repeatedly warned about counterfeit and falsified slimming products sold online, some of which have been found to contain undeclared or banned substances. A genuine route to any of the tablets in this article always runs through a GPhC-registered pharmacy or a UK-registered prescriber, whether that is an in-person pharmacy consultation for Alli or a full clinical assessment for the prescription-only options.
A few signs are worth treating as red flags on their own: a website that will sell a prescription-only medicine with no consultation at all, pricing that looks too low compared with regulated UK providers, packaging or labelling that doesn't match the product you can verify through the manufacturer, or a seller based outside the UK with no way to check its registration. UK law requires registered online pharmacies to display a distance-selling logo linking through to their entry on the General Pharmaceutical Council's register, and you can check that register directly if you're ever unsure whether a seller is genuine.
Safety and eligibility
Eligibility for the prescription-only tablets generally follows the same framework used for the injectable GLP-1 medicines: NICE guidance sets out BMI thresholds, which can be adjusted where relevant comorbidities such as type 2 diabetes are present. Pregnancy, breastfeeding and certain medical histories are contraindications across this medicine class, and a clinician will check your full history before prescribing.
Side effects differ by mechanism. Orlistat's effects are mostly gut-related: oily stools, increased urgency and flatulence, particularly after a high-fat meal, since that is exactly what the medicine is designed to interfere with. The GLP-1 tablets share the same gastrointestinal side-effect profile as the injections, most often nausea, constipation or diarrhoea, especially while the dose is being increased. Whichever tablet you're prescribed, dose changes should always be clinician-led rather than self-managed, and any severe or persistent symptoms should be discussed with a clinician promptly.
Choosing the right option with a clinician
With several licensed tablets now available alongside the injectables, the decision has genuinely become more individual. A clinician will weigh your BMI and health conditions, previous treatment history, tolerability, whether you have a strong preference for a tablet over an injection, and practical factors such as current UK availability; Foundayo, for example, is newly approved and not yet routinely available on the NHS pending a NICE appraisal. Our broader guide to how weight-loss injections work covers the injectable side of that comparison in more depth.
None of the tablets covered here is a shortcut that bypasses clinical assessment, and none suits everyone. What they offer is a wider, genuinely licensed set of options than existed even a couple of years ago, which makes an informed conversation with a clinician more useful than ever before starting. Your clinician will advise based on your individual circumstances.